- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05188729
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
A Phase 2, Multicenter, Open-label, Proof-of-concept Study With Safety Run-in to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Adult Subjects With Basal Cell Carcinoma
This is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, tolerability, MTD, and objective antitumor efficacy of ascending dose strengths of VP-315 when administered intratumorally to adults with biopsy proven basal cell carcinoma (BCC).
The study is expected to enroll approximately 80 subjects with a histological diagnosis of BCC in at least 1 eligible target lesion (confirmed by punch or shave biopsy).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, tolerability, maximum tolerated dose (MTD), and objective antitumor efficacy of ascending dose strengths of VP-315 when administered intratumorally to adults with biopsy proven BCC.
The study is expected to enroll approximately 80 subjects with a histological diagnosis of BCC in at least 1 eligible target lesion (confirmed by punch or shave biopsy).
All enrolled subjects will receive VP-315 intradermal injection on an outpatient basis into up to 2 target lesions. In all Parts of the study (1 or 2, as below), each 7-day treatment week comprises up to 3 consecutive treatment days followed by a no-treatment period of at least 4 days. Dosing will commence in a single target lesion. Once a lesion is observed to be fully necrotic (Part 1, Part 2; Cohorts 1-2 only), treatment of that lesion stops, and treatment of subsequent target lesions (up to 2 total) may continue on Day 1 of the following week. In Part 2, Cohorts 4 and 5, treatment of a second target lesion begins on W2D1 (not based on status of necrosis of target lesion 1).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Wendy Pinson
- Phone Number: (504)732-4588
- Email: Wendy@vial.com
Study Locations
-
-
California
-
San Diego, California, United States, 92123
- Recruiting
- Therapeutics Clinical Research
-
Contact:
- Phone Number: 858-571-6800
-
Principal Investigator:
- Neal D Bhatia, MD
-
-
Florida
-
Saint Augustine, Florida, United States, 32080
- Recruiting
- Florida Center For Dermatology
-
Contact:
- Email: research@fcderm.com
-
Principal Investigator:
- Jonathan Kantor, MD
-
-
Georgia
-
Snellville, Georgia, United States, 30078
- Recruiting
- Gwinnett Dermatology
-
Principal Investigator:
- Jonathan S Weiss, MD
-
-
Maryland
-
Rockville, Maryland, United States, 20850
- Active, not recruiting
- Lawrence J Green, MD LLC
-
-
Texas
-
Dripping Springs, Texas, United States, 78620
- Recruiting
- Austin Institute of Clinical Research - Dripping Springs
-
Principal Investigator:
- Daniel Carrasco, MD
-
Pflugerville, Texas, United States, 78660
- Recruiting
- Austin Institute of Clinical Research - Pflugerville
-
Principal Investigator:
- Edward Lain, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults ≥18 years of age
- Clinically suspected BCC with at least 1 and up to 5 eligible lesion(s) suitable for biopsy and excision
- Willing to refrain from using nonapproved topical agents on, or within 2 cm of, the target BCC lesions and surrounding areas during the treatment period. Subjects should use topical agents that are gentle (eg, Aquaphor, CeraVe) and will not irritate the skin in these areas.
- Willing to refrain from exposure to direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study
- Written informed consent obtained, including consent for tissue to be examined by the central dermatopathologist and stored by the Sponsor or designee
- Willing to undergo BCC surgical excision procedure of target and nontarget BCC lesions after study treatment
- Willing to delay surgical excision of target and nontarget BCC lesions until the end of treatment (EOT) visit
- Provides written consent to allow photographs of the target and nontarget BCC lesion to be used as part of the study data
- Willing to practice a highly effective method of birth control while on study and until 4 weeks after the last treatment. Highly effective birth control includes sexual abstinence, vasectomy, bilateral tubal ligation/occlusion, or a condom with spermicide (men) combined with hormonal birth control or intrauterine device in women.
BCC Lesion Inclusion Criterion
- For punch biopsies: the size of the lesion(s) must be ≥0.5 cm and </=2 cm in the longest diameter prior to punch biopsy.
- Histological diagnosis of nodular, micronodular, or superficial BCC, as confirmed by punch or shave biopsy performed within 28 days of W1D1. (NOTE: HISTORICAL punch or shave biopsies are acceptable, provided that the biopsy was performed according to clinical standard of care and was collected within the 28 days prior to Screening.)
Exclusion Criteria:
- Presence of known or suspected systemic cancer
- Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit
- Treatment with systemic immunotherapy, immunomodulators or immunosuppressants within the 12 weeks prior to the screening period
- Genetic or nevoid conditions (eg, Gorlin / basal cell nevus syndrome, xeroderma pigmentosum)
Clinically significant laboratory values, as assessed by the investigator, for the tests listed in the Schedule of Assessments, including:
- serum creatinine >1.5× the upper limits of normal and
- serum tryptase concentration >11.4 ng/mL
Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the subject at undue risk, such as, but not limited to:
- Uncontrolled infection or infection requiring antibiotics
- Uncontrolled cardiac failure: Classification III or IV New York Heart Association
- History of cerebrovascular or cardiac disorders, or subjects at particular risk of sequelae following a short hypotensive episode, including subjects with systolic BP <110 mmHg and/or diastolic BP <70 mmHg at screening or Day 1
- Uncontrolled systemic or gastrointestinal inflammatory conditions
- Known bone marrow dysplasia
- History of positive tests for human immunodeficiency virus/acquired immunodeficiency syndrome or active hepatitis B or C
- History of systemic autoimmune disease requiring anti-inflammatory or immunosuppressive therapy within 3 months prior to Day 1, with the following exceptions:
i. Subjects with a history of autoimmune thyroiditis are eligible provided the subject requires only thyroid hormone replacement therapy and disease has been stable for ≥1 year
ii. Subjects with well-controlled type I diabetes (in the opinion of the investigator) are eligible
h. Known mast cell activation syndrome, mastocytosis, or chronic idiopathic urticaria
- Known sensitivity to any of the ingredients in the study medication
- Elective surgery within 4 weeks prior to the screening visit, during the study, or 4 weeks after the treatment period
- Evidence of current chronic alcohol or drug abuse
- Current enrollment in an investigational drug or device study or participation in such a study within 4 weeks of the screening visit
- In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions of the protocol and complete the study
- Females who are pregnant or breastfeeding
BCC Lesion Exclusion Criteria
- Recurrent or previously treated lesions
- Lesions within 1 cm of the eyelids or lips, or on the hands, feet, ears, nose, and genitalia
- Histological evidence of any other tumor in the biopsy specimen
- Histological evidence of infiltrative, desmoplastic, sclerosing, or morpheaform BCC subtypes in the biopsy specimen
Medium- and high-risk basal cell carcinomas as defined by the National Comprehensive Cancer Network (NCCN) or Mohs Appropriate Use Criteria (ie, BCCs eligible for Mohs surgery).
TARGET LESION EXCLUSION ONLY:
- For subjects with severe stasis dermatitis, target BCC lesions may not be on the lower extremities
Within 2 cm of the target BCC lesion(s):
- Treatment with the following topical agents within the 12 weeks prior to the screening visit: aminolevulinic acid, 5-fluorouracil, corticosteroids, diclofenac, imiquimod, ingenol mebutate
- Treatment with surgical excision, or curettage within the 2 weeks prior to the screening visit
- Evidence of dermatological disease or confounding skin condition that may interfere with clinical evaluation (ie, psoriasis, atopic dermatitis, eczema, propensity to form keloids or hypertrophic scarring)
- Use of topical immunomodulators during study
- Within 5 cm of the target BCC lesion(s): history of any skin cancer, except for other currently identified target and nontarget BCC lesions
- Target BCC lesion is in the area of prior resurfacing procedure with CO2 laser or any photodynamic and phototherapy treatment within the 3 months prior to the screening visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1 LTX-315 Safety Run-in
Part 1: Starting total daily dose of LTX-315 will be 2 mg for the first subject.
Subjects will receive ascending once daily doses increasing in 1 mg increments for up to 3 days in a 7-day treatment week until the first lesion is necrosed or a DLT occurs
|
LTX-315 once-daily dosing; starting total daily dose of 2 mg for the first subject.
Ascending once-daily 1 mg dosing increments (eg, 2 mg on Day 1, 3 mg on Day 2).
Subjects may be treated for a maximum of 2 weeks and a maximum total daily dose of 8 mg in Part 1.
The starting dose will be escalated between subject cohorts in 1-mg increments after the previous cohort has completed Week 1 dosing (the DLT observation period).
Other Names:
|
Experimental: Part 2 VP-315 Regimen Finding
Part 2: VP-315 once-daily dosing; total daily dose of 8 mg in up to 5 cohorts
Cohorts 4 and 5, the total daily dose of VP-315 (8.0 mg) will be divided into a split dose; the first dose is not to exceed 2.4 mg (30% of 8 mg dose), and the remaining dose will not exceed 5.6 mg (70% of 8 mg dose) and administered 15 minutes apart (not to exceed 30 minutes).
PK data will be collected in the Cohorts 4 and 5 expansion groups. |
VP-315 once-daily dosing; Part 2 will be initiated upon completion of Part 1 to determine the optimal dosing regimen of VP-315.
There were no DLTs observed in Part 1 of the study and the maximum dose of 8 mg was achieved.
Therefore, the dose to be evaluated in Part 2 will be a total daily dose of 8 mg in 4 Cohorts.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Percentage of subjects with discontinuations due to adverse events
Time Frame: Up to 9 weeks
|
Subjects who discontinued the study due to adverse event
|
Up to 9 weeks
|
Part 1: Percentage of subjects with dose-limiting toxicities (DLTs)
Time Frame: Day 4 (Safety Assessment)
|
Subjects with pre-determined dose-limiting toxicities such as hypotension (specific criteria); significant elevation of serum tryptase; Grade 2 or higher adverse event (with specific criteria)
|
Day 4 (Safety Assessment)
|
Part 1: Percentage of subjects with Cutaneous Reaction by severity
Time Frame: Up to 9 weeks
|
Evaluation of the tissue condition at the treatment site for the presence and severity of each of the following cutaneous reactions; Erythema, Induration, Swelling, Blister Formation, Desquamation, Erosion, Ulceration, Necrosis by a scale of None; Mild; Moderate; Severe.
|
Up to 9 weeks
|
Part 2: Percent of subjects with adverse events
Time Frame: Up to 15 weeks
|
Subjects with adverse events
|
Up to 15 weeks
|
Part 2: Percentage of subjects with discontinuations due to adverse events
Time Frame: Up to 15 weeks
|
Subjects that discontinued study due to adverse events
|
Up to 15 weeks
|
Part 2: Percent of subjects with Treatment Related Adverse Events of Special Interest (TRAEs SI)
Time Frame: Treatment Week 1 Day 1
|
Subjects with pre-determined TRAEs of SI such as hypotension (specific criteria); significant elevation of serum tryptase; Grade 2 or higher adverse event (with specific criteria)
|
Treatment Week 1 Day 1
|
Part 2: Percent of subjects with Treatment Related Adverse Events of Special Interest (TRAEs SI)
Time Frame: Treatment Week 1 Day 2
|
Subjects with pre-determined TRAEs of SI such as hypotension (specific criteria); significant elevation of serum tryptase; Grade 2 or higher adverse event (with specific criteria)
|
Treatment Week 1 Day 2
|
Part 2: Percent of subjects with Treatment Related Adverse Events of Special Interest (TRAEs SI)
Time Frame: Treatment Week 1 Day 3
|
Subjects with pre-determined TRAEs of SI such as hypotension (specific criteria); significant elevation of serum tryptase; Grade 2 or higher adverse event (with specific criteria)
|
Treatment Week 1 Day 3
|
Part 2: Percent of subjects with Treatment Related Adverse Events of Special Interest (TRAEs SI)
Time Frame: Treatment Week 2 Day 1
|
Subjects with pre-determined TRAEs of SI such as hypotension (specific criteria); significant elevation of serum tryptase; Grade 2 or higher adverse event (with specific criteria)
|
Treatment Week 2 Day 1
|
Part 2: Percent of subjects with Treatment Related Adverse Events of Special Interest (TRAEs SI)
Time Frame: Treatment Week 2 Day 2
|
Subjects with pre-determined TRAEs of SI such as hypotension (specific criteria); significant elevation of serum tryptase; Grade 2 or higher adverse event (with specific criteria)
|
Treatment Week 2 Day 2
|
Part 2: Percent of subjects with Treatment Related Adverse Events of Special Interest (TRAEs SI)
Time Frame: Treatment Week 2 Day 3
|
Subjects with pre-determined TRAEs of SI such as hypotension (specific criteria); significant elevation of serum tryptase; Grade 2 or higher adverse event (with specific criteria)
|
Treatment Week 2 Day 3
|
Part 2: Percentage of subjects with Cutaneous Reaction by severity
Time Frame: Up to 105 days
|
Evaluation of the tissue condition at the treatment site for the presence and severity of each of the following cutaneous reactions; Erythema, Induration, Swelling, Blister Formation, Desquamation, Erosion, Ulceration, Necrosis by a scale of None; Mild; Moderate; Severe.
|
Up to 105 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 2: Percentage of subjects with clinical clearance of treated lesion(s) at excision
Time Frame: Day 84-91
|
Clinical clearance of treated lesion at excision as determined by visual assessment (no residual tumor seen on visual inspection)
|
Day 84-91
|
Part 2: Percentage of subjects with histological clearance of treated lesion(s) at excision
Time Frame: Day 84-91
|
Subjects with histological clearance of treated lesion(s) at excision
|
Day 84-91
|
Part 2: Percentage of subjects with abscopal effect at excision
Time Frame: Day 84-91
|
Abscopal effect as determined by clinical and histological clearance of nontreated lesions at excision
|
Day 84-91
|
Part 2: Mean estimated remaining tumor volume at excision
Time Frame: Day 84-91
|
Estimate of remaining tumor volume (necrotic cells:tumor cells) at excision
|
Day 84-91
|
Part 2: Percent of subjects with Physician's Global Assessment by scale
Time Frame: Up to 105 days
|
Physician's global assessment of improvement per lesion as measured by the following scale: 100% improvement, no visible tumor; 75% to <100% improvement; 50% to <75% improvement; 25% to <50% improvement; up to 25% improvement; no change; worse
|
Up to 105 days
|
Part 2 (Cohorts 4 and 5 expansion groups): Plasma concentrations of VP-315
Time Frame: Day 1-2
|
Pharmacokinetics (PK) of an 8 mg dose of VP-315 administered with the optimal dosing regimen
|
Day 1-2
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Neal Bhatia, MD, Therapeutics Clinical Research
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VP-315-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingBreast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast CarcinomaUnited States
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Fudan University; RenJi Hospital; Xinhua Hospital, Shanghai... and other collaboratorsRecruitingGlottic Carcinoma | Supraglottic Carcinoma | Subglottic Carcinoma | Pyriform Sinus Carcinoma | Postcricoid Carcinoma | Posterior Pharyngeal Wall CarcinomaChina
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterEmbr Labs, Inc.Active, not recruitingHot Flashes | Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In SituUnited States
-
Institut BergoniéCompletedIntraductal Carcinoma and Lobular Carcinoma in SituFrance
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
University of UtahNational Cancer Institute (NCI)RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast CarcinomaUnited States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
Clinical Trials on LTX-315 Part 1
-
Lytix Biopharma ASKarolinska University Hospital; Oslo University HospitalCompletedCancer With Transdermal Accessible TumourSweden, Norway
-
Lytix Biopharma ASHerlev HospitalCompletedSoft Tissue SarcomaDenmark
-
Lytix Biopharma ASKael-GemVax Co., Ltd.Completed
-
Lytix Biopharma ASICON plc; TheradexCompletedMelanoma | Lymphoma | Cancer | Breast Cancer | Head and Neck Cancer | Triple-Negative Breast CancerUnited Kingdom, France, Norway, Belgium, Italy
-
Lytix Biopharma ASCompletedNon-bullous ImpetigoDominican Republic
-
Lytix Biopharma ASLaboratory Corporation of America; OWLActive, not recruitingAdvanced MelanomaUnited States, Spain, France, Norway
-
Novartis PharmaceuticalsCompletedPrimary Biliary CholangitisUnited States, Germany, Russian Federation, Canada, United Kingdom, Poland
-
PfizerCompletedRheumatoid Arthritis | Healthy VolunteersUnited States
-
Ichnos Sciences SAGlenmark Pharmaceuticals S.A.CompletedModerate to Severe Atopic DermatitisUnited States, Canada, Czechia, Germany, Poland
-
Chiesi Farmaceutici S.p.A.CompletedCystic Fibrosis | Non-Cystic Fibrosis BronchiectasisBelgium